Michael Clearfield - Concepedia

Author

Michael Clearfield

Also Known As

M B Clearfield, M CLEARFIELD, M Clearfield, M. B. Clearfield, M. Clearfield, M.B. Clearfield, MICHAEL CLEARFIELD, Michael B Clearfield, Michael B. Clearfield, Michael Clearfield

Publications

16.7K

Citations

H-Index

Concepts

All Affiliations

University of North Texas University of North Texas Health Science Center Cornell University Wilford Hall Ambulatory Surgical Center Touro University California

About

Michael Clearfield is an author at University of North Texas specializing in medicine, cardiovascular disease, and coronary heart disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	2.3K
2	Public Health	9	9	1.4K
3	Epidemiology	8	8	1.3K
4	Health Sciences	1	1	59
5	Cardiothoracic Surgery	1	1	45

Michael Clearfield

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels John R. Downs, Michael Clearfield, Stephen E. Weis, JAMA	1998	5.3K
Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events Paul M. Ridker, Nader Rifai, Michael Clearfield, New England Journal of Medicine	2001	1.6K
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events Paul M. Ridker, Brendan M. Everett, Aruna D. Pradhan, New England Journal of Medicine	2018	1.2K
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events Paul M. Ridker, Nader Rifai, Michael Clearfield ACC Current Journal Review InflammationThrombosisPrimary PreventionCardiovascular DiseasePharmacology	2001	763
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Antonio M. Gotto, Edwin J. Whitney, Evan A. Stein, Circulation	2000	566
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Cynthia J. Girman, Thomas Rhodes, Michele Mercuri, The American Journal of Cardiology Metabolic SyndromeCardiovascular EpidemiologyCardiovascular DiseaseHealth PolicyMajor Coronary Events	2004	531
Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis Brendan M. Everett, Aruna D. Pradhan, Daniel H. Solomon, American Heart Journal InflammationThrombosisHeart FailureVascular DiseaseCardiovascular Disease	2013	363
C-reactive protein: a new risk assessment tool for cardiovascular disease. Michael Clearfield PubMed Vascular DiseaseImmunologyHyperlipidemiaPreventive CardiologyCoronary Artery Disease	2005	164
Air force/texas coronary atherosclerosis prevention study (afcaps/texcaps): Additional perspectives on tolerability of long-term treatment with lovastatin John R. Downs, Michael Clearfield, H A Tyroler, The American Journal of Cardiology Percutaneous Coronary InterventionCardiovascular EpidemiologyCardiovascular DiseaseLong-term TreatmentCardiovascular Pharmacology	2001	137
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Efficacy and Tolerability of Long-Term Treatment with Lovastatin in Women Michael Clearfield, John R. Downs, Stephen E. Weis, Journal of Women s Health & Gender-Based Medicine	2001	99

Page 1